We’re proud to help fund the first Zebrafish models of CLOVES
We’re pleased to announce a $100,000 research donation to the University of Edinburgh – Patton Lab – to develop zebrafish models of CLOVES. Dr. Hannah Brunsdon has written a lay summary about this project below. “People with CLOVES syndrome…
.
First publication from the VACOM Research Study
Since 2021, CLOVES Syndrome Community has supported the work of Dr. Bryan Sisk, Assistant Professor of Pediatric Hematology and Oncology at Bioethics Research Center with conducting a research study titled “Vascular anomalies communication” (VACOM). Vascular anomalies are a group of…
.
Thank you to PrimeLending
Smashing into Spring! Thank you to our friends at PrimeLending, who chose CLOVES Syndrome Community as the beneficiary for their 1st Annual Smash Event at the Riot Room in Rochester! The event was an overwhelming success raising over $12,000 in…
.
Our 2022 Research Grant Recipient is Dr. Wen Yi Aw
The Scientific and Medical Advisory Board and Board of Directors of CLOVES Syndrome Community are pleased to award Dr. Wen Yih Aw of The University of North Carolina/Chapel Hill a $50,000 grant for her project titled “Non-canonical signaling and therapeutic targets for vascular…
.
Exciting news for the CLOVES/PROS community: FDA approves Novartis Vijoice (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1. PROS is a spectrum of rare conditions and is characterized by atypical overgrowths and anomalies in blood…
.